Study of Etonogestrel Implant Use as Emergency Contraception Evaluating Ovulation Suppression When Inserted Before LH Surge Single-Group Pilot Pharmacodynamic Trial in Women Ages 18 to 40

What this Trial Is About

This research aims to study the use of an etonogestrel implant as a form of emergency contraception in females aged 18 to 40 years. The study evaluates whether placing the implant before the luteinizing hormone LH surge can inhibit ovulation. This pilot pharmacodynamic study is unique because it investigates a novel timing for implant insertion that may improve patient access and reduce the need for additional emergency contraception, supported by prior findings on etonogestrel levels rising quickly after insertion. Participants will receive the etonogestrel contraceptive implant during their second menstrual cycle before ovulation occurs. The implant insertion is timed once the dominant ovarian follicle reaches a certain size but before the LH surge begins. This single-group, open-label study focuses solely on this intervention and does not include a comparison group or placebo. During the study, participants will be monitored over 7 days to assess serum progesterone levels, ovarian follicle size, and LH hormone levels to evaluate ovulation status. Participants must abstain from medications affecting etonogestrel metabolism and will undergo hormone measurements and ultrasound assessments. The total study duration spans from enrollment through the monitoring period, with careful safety and adherence tracking by the research team.

Etonogestrel Implant as Emergency Contraception